Scalp Psoriasis

Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first “dedicated trial” to demonstrate sustainable efficacy of an anti-interleukin-23 inhibitor for the condition.

The VISIBLE trial demonstrated that intentional efforts to recruit and retain patients with skin of color result in a speedy enrollment process and diverse patient pool, according to a study.

As the year comes to a close, Healio Dermatology has assembled this year’s top psoriasis articles. 

Roflumilast foam 0.3% improved patient-reported outcomes in scalp and body psoriasis, according to a poster presentation at the Fall Clinical Dermatology Conference.

Deucravacitinib proved to be efficacious in the treatment of moderate to severe scalp psoriasis and less extensive overall psoriasis, according to two presentations at the European Academy of Dermatology and Venerology Congress.

Tildrakizumab was efficacious in the treatment of patients with moderate to severe plaque psoriasis affecting the scalp and presented no new safety signals, according to a study.

Pediatric patients with psoriasis experienced significant improvement with oral apremilast treatment, according to phase 3 trial results.

Patients with skin of color that suffer from scalp psoriasis saw significant improvement in their disease severity, scalp itch and quality of life outcomes when treated with Tremfya, according to newly released phase 3 results.

The efficacy of deucravacitinib was superior to placebo and apremilast in treating scalp psoriasis, according to pooled results of two studies.

In new phase 4 results, Vtama cream 1% demonstrated strong, rapid efficacy for the treatment of adults with plaque psoriasis in the head and neck, Dermavant announced in a press release.